Log in or Sign up for Free to view tailored content for your specialty!
Skin Care News
FDA grants fast track designation to ATR-04 for cancer therapy-induced skin rash
The FDA has granted fast track designation to topically applied ATR-04 for the treatment of moderate to severe epidermal growth factor receptor inhibitor-associated dermal toxicity, Azitra announced in a press release.
Catch up with top Healio Dermatology news from August
Celebrity news and nutrition stories led Healio Dermatology’s most-read articles in August.
Spontaneous chronic urticaria improvement seen with Dupixent treatment
Patients with chronic spontaneous urticaria experienced a marked improvement with Dupixent treatment, according to phase 3 trial results released by Regeneron.
Log in or Sign up for Free to view tailored content for your specialty!
Endocrine-disrupting chemicals from personal care products found in young children
The use of personal care products was associated with endocrine-disrupting chemicals called phthalates in children aged as young as 4 years, according to a study.
No changes to CDC guidelines recommending children with lice do not need to leave school
As kids return to school, the CDC has reminded the public that children with lice do not need to cut their school day short and be sent home early.
Low-dose IL-2 promising in bullous pemphigoid treatment
A low dose of interleukin-2 therapy showed positive results in the treatment of bullous pemphigoid with an early onset of response, according to a study.
‘Clear as mud’: Why the FDA has not approved new sunscreen ingredients
The FDA has not approved a new sunscreen ingredient since the 1990s, leaving consumers and clinicians wondering why.
Skin care plays large role in managing challenges of adult acne
A panel of experts shared consensus statements on how to best manage adult acne, according to a study.
FDA clears development of drug to treat cancer therapy-induced skin rash
The FDA has cleared an investigational new drug application for a first-in-human phase 1/2 study of ATR-04 for moderate to severe dermal toxicity from epidermal growth factor receptor inhibitors, Azitra Inc. announced in a press release.
Phase 3 study of TMB-001 for treatment of congenital ichthyosis fails to meet endpoints
Timber Pharmaceutical’s study investigating the use of a new topical ointment formulation of isotretinoin for moderate to severe congenital ichthyosis did not achieve its endpoints, LEO Pharma announced in a press release.
-
Headline News
‘The mind is medicine’: How virtual reality can cool bothersome hot flashes
September 18, 20244 min read -
Headline News
CDC: Close contact of Missouri bird flu case had symptoms but was not tested
September 17, 20242 min read -
Headline News
Metformin use may lower risk for long COVID in adults with type 2 diabetes
September 18, 20243 min read
-
Headline News
‘The mind is medicine’: How virtual reality can cool bothersome hot flashes
September 18, 20244 min read -
Headline News
CDC: Close contact of Missouri bird flu case had symptoms but was not tested
September 17, 20242 min read -
Headline News
Metformin use may lower risk for long COVID in adults with type 2 diabetes
September 18, 20243 min read